Huang YQ, Huang ZW, Zhang XJ. Targeting nuclear factor erythroid 2-related factor 2-regulated ferroptosis to treat nervous system diseases. World J Clin Cases 2024; 12(33): 6655-6659 [PMID: 39600481 DOI: 10.12998/wjcc.v12.i33.6655]
Corresponding Author of This Article
Zheng-Wei Huang, PharmD, Teacher, College of Pharmacy, Jinan University, No. 855 East Xingye Dadao, Panyu District, Guangzhou 510006, Guangdong Province, China. huangzhengw@jnu.edu.cn
Research Domain of This Article
Pharmacology & Pharmacy
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Nov 26, 2024; 12(33): 6655-6659 Published online Nov 26, 2024. doi: 10.12998/wjcc.v12.i33.6655
Targeting nuclear factor erythroid 2-related factor 2-regulated ferroptosis to treat nervous system diseases
Ye-Qi Huang, Zheng-Wei Huang, Xue-Juan Zhang
Ye-Qi Huang, Zheng-Wei Huang, Xue-Juan Zhang, College of Pharmacy, Jinan University, Guangzhou 510006, Guangdong Province, China
Co-corresponding authors: Zheng-Wei Huang and Xue-Juan Zhang.
Author contributions: Huang YQ was responsible for writing original draft preparation, review, and editing; Huang ZW was responsible for original draft preparation, conceptualization supervision, and funding acquisition; Zhang XJ was responsible for supervision and funding acquisition; all of the authors read and approved the final version of the manuscript to be published.
Supported byThe Guangdong Basic and Applied Basic Research Foundation, China, No. 2024A1515011236.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Zheng-Wei Huang, PharmD, Teacher, College of Pharmacy, Jinan University, No. 855 East Xingye Dadao, Panyu District, Guangzhou 510006, Guangdong Province, China. huangzhengw@jnu.edu.cn
Received: May 22, 2024 Revised: September 11, 2024 Accepted: September 19, 2024 Published online: November 26, 2024 Processing time: 127 Days and 17.8 Hours
Abstract
By critically examining the work, we conducted a comprehensive bibliometric analysis on the role of nuclear factor erythroid 2-related factor 2 (NRF2) in nervous system diseases. We also proposed suggestions for future bibliometric studies, including the integration of multiple websites, analytical tools, and analytical approaches, The findings presented provide compelling evidence that ferroptosis is closely associated with the therapeutic challenges of nervous system diseases. Targeted modulation of NRF2 to regulate ferroptosis holds substantial potential for effectively treating these diseases. Future NRF2-related research should not only focus on discovering new drugs but also on designing rational drug delivery systems. In particular, nanocarriers offer substantial potential for facilitating the clinical translation of NRF2 research and addressing existing issues related to NRF2-related drugs.
Core Tip: Based on the original paper, this study highlights two primary points: Bibliometric methodologies and future perspectives for nuclear factor erythroid 2-related factor 2 (NRF2) research. We emphasize the need for broader literature databases and diversified analysis methods in bibliometric research. Additionally, we highlight the importance of NRF2 modulation in regulating ferroptosis for treating nervous system diseases and discuss how nanoparticle drug delivery systems may overcome challenges associated with NRF2-related drugs.
